Search a ticker

Categories
Featured Health Care Stocks Investing Stock Market Today

Top Stocks To Buy This Week? 4 Health Care Stocks To Watch

Check out these trending names in the health care industry.

best stocks to buy this week

Should Investors Be Watching These Top Health Care Stocks Right Now?

When it comes to answering the question of “which stocks to invest in now”, investors may want to consider health care stocks. With pharmaceutical giants and emerging names in biotech, there is plenty of variety in the stock market today. If anything, the health care industry is among the most vital markets in our world today. From helping us maintain and improve our quality of life to developing cures for deadly diseases, the importance of the sector can’t be overstated. Even now, as the world continues to deal with the coronavirus pandemic, things could be heating up in the health care world again.

Just this week, White House chief medical advisor Dr. Anthony Fauci highlighted the rising threat of the Delta variant of COVID-19. According to Dr. Fauci, this variant of concern could be the dominant strain in the U.S. in the next few weeks. Not to mention, the World Health Organization named it the “fastest and fittest coronavirus strain yet”. As a result, health care companies across the board stand to benefit. On one hand, Medicare providers like Clover Health (NASDAQ: CLOV) would see an uptick in customers. This could happen as more Americans place a higher priority on their day-to-day health. On the other hand, coronavirus vaccine companies such as Moderna (NASDAQ: MRNA) would also be hard at work addressing variants. On that note, take a look at these four top health care stocks making headlines in the stock market now.

Top Health Care Stocks To Watch Before July

GlaxoSmithKline Plc

GSK is a multinational pharmaceutical company with a wide portfolio of treatments and drugs. It is a global healthcare company that has developed many life-changing drugs in the last 20 years. For instance, the company was the first to develop the malaria vaccine. It also has legacy products like Amoxicillin, an antibiotic used to treat a number of bacterial infections. Shares of GSK stock are up by over 18% since March.

On Wednesday, the company announced plans to turn its consumer health care business into a separately listed company. This will also strengthen drug development at its pharmaceutical business with an $11 billion windfall. The resulting New GSK will be a growth company that has new ambitions for patients and shareholders. It would strengthen its R&D and commercial initiatives and also transform its group structure and capital allocation. Also, GSK expects to improve adjusted operating margin from the mid-20s% in 2021 to over 30% by 2026. Profit growth will be driven by a combination of strong revenue growth from new vaccines and specialty medicines, improving operational performance, and benefits from the transformation of recent years. Given this exciting piece of news, will you consider watching GSK stock?

Source: TD Ameritrade TOS

Read More

Entera Bio Ltd

Entera is a biotech company that develops orally delivered large molecule therapies. Its proprietary oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body. ENTX stock currently trades at $6.03 as of 9:40 a.m. ET and is up by over 30% this week. Investors seem to be responding to news that the company recently released.

Diving in, Entera announced excellent topline Phase 2 bone mineral density (BMD) results for its lead candidate EB613 for the treatment of osteoporosis. If approved, EB613 will be the first oral bone-building product to treat osteoporosis patients. In detail, the company reported that subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 months. Spiros Jamas, CEO of Entera Bio had this to say, “We are looking forward to an end of Phase 2 meeting with the FDA. More detailed results will also be presented in a future scientific conference and publications. The company will evaluate potential additional osteoporosis market opportunities specifically related to increases in hip BMD.” For this reason, is ENTX stock worth adding to your portfolio?

Source: TD Ameritrade TOS

[Read More] What Are The Best Stocks To Invest In? 5 EV Stocks To Watch Now

Ocugen Inc.

Ocugen is a biopharmaceutical company that develops and commercializes transformative therapies to treat rare and underserved eye diseases. The company has also made great strides in developing its coronavirus vaccine. OCGN stock has increased by over 2,000% in valuation in the last year. On June 16, 2021, the company announced that it will join the Russell 3000 Index, which measures the performance of the largest U.S. companies.

Last week, the company also announced that it has selected Jubilant HollisterStier as its manufacturing partner for its coronavirus vaccine candidate, Covaxin for commercial manufacturing in the U.S. and Canadian market. This is ahead of the company preparing to submit for regulatory approval to the FDA and Health Canada. Its vaccine candidate has shown strong results conducted to date, including an efficacy rate of 78% overall efficacy and 100% in severe coronavirus including hospitalizations. All things considered, will you watch OCGN stock?

Source: TD Ameritrade TOS

[Read More] 3 Growth Stocks That Could Be Better Investments Than AMC Stock Right Now

Veeva Systems Inc.

Last but not least, we have Veeva Systems Inc. For the uninitiated, the California-based computer software company is a major name in the health care space now. This is mainly thanks to its cloud-computing services which primarily aid the pharmaceutical and life sciences industries. Through its cloud-computing services, Veeva empowers customers at every step of the regulatory process. By extension, the company helps customers accelerate the said process. Notably, Veeva serves over 1,000 health care organizations, ranging from the leading players in the field to upcoming biotech names. These include the likes of AstraZeneca (NASDAQ: AZN), bluebird bio (NASDAQ: BLUE), and Eli Lilly & Co. (NYSE: LLY), to name a few. Seeing as VEEV stock is currently up by over 17% in the past month, investors appear to be keen on the company’s growth prospects now.

Likewise, more health care companies seem to share the same sentiment now. On Tuesday, Veeva revealed that it is working with Oval Medical Technologies and inveox GmbH, two emerging Medtech companies. These new clients will be using Veeva’s Vault Quality Suite of applications to modernize their quality management. inveox CEO Dominik Sievert commented that Veeva’s services make the company “well-equipped” to accelerate the development of products while complying with industry regulations. Given the facilitating role of Veeva in the life-science industry, we could be looking at long-term demand for its services. As such, would you consider adding VEEV stock to your July watchlist?

Source: TD Ameritrade TOS

By Joe Samuel

Joe Samuel is a dedicated stock market researcher and financial contributor. His love for the stock market started at a young age learning from his grandfather. Joe earned a bachelor of science degree in corporate finance and business management. After finishing college, he went the route of an entrepreneur starting numerous businesses and eventually became a financial contributor to a number of outlets including Seeking Alpha, Invesitng.com, and actively contributes to FactSet. At StockMarket.com, Joe looks for emerging stories. One of his traits is identifying new trends before they become mainstream. Whether it’s a biopharmaceutical company debuting a novel treatment or the next technology start-up developing a new platform, Joe looks to be on the cutting edge of that trend.

After years of living in New York, he made the move to Miami, Florida where he’s become an active member of the finance community. Joe has worked with early-stage companies in marketing and consulting capacities, which has given him an opportunity to see what makes companies tick. His viewpoint is that while corporate news is vital to any investment, it’s what isn’t “right in front of you” that can make a good investment great. His approach to the markets is one that aims to deliver information that might not be well-known. But through deep research and diligence, Joe has written about and been able to uncover time-sensitive information when seconds matter in the stock market today.

Joe enjoys covering several stock market sectors. These include commodities, finance, biotechnology, and technology; specifically AI & machine learning. His no-nonsense approach to the market gives readers a cut and dry view of the news that matters most and topics beginning to emerge as new trends in the stock market. He was early to the table with calls on things like the last gold rush in 2019 and has been able to identify influential events and how they could impact certain industries.

During his free time, he enjoys spending time with his family and polishing up one new stock market trends. He’s also an avid car enthusiast with a passion for classic and muscle cars.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments